Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
CAR T-cell therapy is a form of immunotherapy used to treat some adults with lymphoma. The treatment involves utilizing a patient's own T cells and genetically modifying them in the laboratory to recognize a protein on their cancer cells. The modified T cells, known as CAR T cells, are then returned to the patient to find and kill cancerous cells throughout the body.
Researchers are assessing a new type of therapy in young people with solid tumors that keep growing even after treatment. The therapy is called afamitresgene autoleucel. The people in this study have synovial sarcoma, malignant peripheral nerve sheath tumor (MPNST), neuroblastoma, or osteosarcoma. In addition, they have tested positive for the HLA-A*02 gene and their cancers make a protein called MAGE-A4. This protein plays a role in cancer growth.
Researchers want to see if tumor-treating fields (TTFields) are safe and practical for people with lung adenocarcinoma before surgery. Lung adenocarcinoma is a type of lung cancer. If you join this study, you will get treatment with TTFields for up to 3 weeks before lung cancer surgery.
The purpose of this study is to see if delivering laser light directly to the prostate to activate a light-sensitive drug is a safe and effective treatment for prostate cancer that has come back after radiation therapy. The goal of this treatment is to eliminate any remaining prostate cancer cells. This approach is a form of photodynamic therapy (PDT).
Researchers are comparing RMC-6236 with standard therapy in people with advanced pancreatic cancer. The people in this study have pancreatic cancer that has metastasized (spread) and keeps growing even after treatment.
Researchers are assessing different doses of FT825 alone or with cetuximab to treat people with advanced solid tumors. Their tumors have high levels of the HER2 protein. Altered HER2 proteins can fuel cancer growth. 
Researchers want to find the best dose of EVM14 when used alone or with pembrolizumab in people with solid tumors. The people in this study have a solid tumor that keeps growing after treatment and has spread. This study includes people with:
Breast cancer (TNBC) and non-small cell lung cancer (NSCLC) that spread to other parts of the body (metastasize) are usually treated with chemotherapy, immunotherapy, targeted therapies, and/or radiation therapy. In this study, researchers want to see if using stereotactic body radiosurgery (SBRT) to all metastatic tumors plus standard therapy is more effective than standard therapy alone in patients with oligometastatic TNBC or NSCLC (five or fewer metastatic tumors).
Researchers are seeking the best dose of revumenib (SNDX-5613) to give with chemotherapy in people with acute myeloid leukemia (AML). The people in this study have AML that has not yet been treated. In addition, their cancers have a mutation (change) in the KMT2Ar, NPM1c, or NUP98r gene.
